Drugs / ORIC-533
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05227144 | Jan 2022 → Mar 2025 | refractory plasma cell neoplasm | ORIC Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORIC-533 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05227144 ↗ |
| Action | Inhibit | “inhibitor of CD73” NCT05227144 ↗ |
| Modality | Small molecule | “small molecule inhibitor” NCT05227144 ↗ |
| Route | Oral | “ORIC-533 dosed orally, once per day of each consecutive 28-day cycle” NCT05227144 ↗ |